Bursa Türkiye

Intravenous immunoglobulin (IVIG) is widely used in dermatology for severe and refractory immune-mediated diseases; however, comprehensive real-world data regarding its effectiveness and safety across diverse dermatologic conditions remain limited. To evaluate the clinical outcomes and adverse events associated with IVIG therapy in patients with dermatologic diseases treated in routine clinical practice.

1 Introduction Lung cancer is the second most common type of cancer worldwide after breast cancer, and it ranks as the first leading cause of cancer-related deaths. According to the latest data, it is estimated that there were about 2.21 million new cases of lung cancer in 2020 [1, 2]. Five-year survival rates are 59% for stage 1/2 lung cancer, 31.7% for stage 3, and this rate unfortunately decreases to 5.8% in the metastatic patients [3].